

## Special Issue

# Antibodies in Influenza Vaccine and Therapeutic Design

### Message from the Guest Editor

A universal influenza vaccine that provides broad protection has eluded influenza virus researchers for decades. The effectiveness of current influenza vaccines is limited by antigenic drift, antigenic shift and suboptimal responses in high-risk groups. To overcome these issues, there has been a renewed interest in developing influenza vaccines that induce broadly-reactive antibodies targeting conserved regions of the influenza virus (such as the hemagglutinin stem). Passive infusions of monoclonal or polyclonal antibodies have also demonstrated promising results as a potential therapeutic intervention for severe influenza infections. As such, antibodies are central to the development of more universal influenza vaccines and novel anti-viral therapies. In this Special Issue, we invite you to submit research articles and reviews on a range of research topics relating to the role of Antibodies in Influenza Vaccine and Therapeutic Design.

---

### Guest Editor

Dr. Hillary Anne Vandervan

College of Public Health, Medical & Vet Sciences, James Cook University, Douglas, QLD 4811, Australia

---

### Deadline for manuscript submissions

closed (10 June 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/47488](https://mdpi.com/si/47488)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).